MATNIB 100MG TABLET contains Imatinib which belongs to the group of medicines called Tyrosine Kinase Inhibitors. It is used in adults, children and adolescents to treat chronic myeloid leukaemia (CML) (a form of leukaemia in which certain abnormal white cells (named myeloid cells) start growing out of control) and philadelphia chromosome positive acute lymphoblastic leukaemia (Ph-positive ALL) (a form of leukaemia in which certain abnormal white cells (named lymphoblasts) start growing out of control).
Also, it is used in adults only to treat myelodysplastic/myeloproliferative diseases (MDS/MPD) (a group of blood diseases in which some blood cells start growing out of control), hyper eosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) (a blood diseases in which some blood cells (named eosinophils) start growing out of control), gastrointestinal stromal tumours (GIST) (cancer of the stomach and bowels) and dermatofibrosarcoma protuberans (DFSP) (cancer of the tissue beneath the skin in which some cells start growing out of control).
Before taking MATNIB 100MG TABLET, inform your doctor if you have or ever had kidney, liver or heart problems, hepatitis B infection and thrombotic microangiopathy (symptoms include bruising, bleeding, fever, fatigue and confusion).
MATNIB 100MG TABLET is generally not recommended for use in pregnant women unless advised by the doctor and it is not recommended for use in breastfeeding women. MATNIB 100MG TABLET should be used with caution in children, adolescents and elderly patients (aged 65 years and above).
The most common side effects of taking MATNIB 100MG TABLET are nausea, vomiting, diarrhea, headache, weight gain, loss of appetite, disturbed sense of taste, blurred vision and weakness. Consult your physician if any of the side effects worsen.